Expertise in
18
conditions

Alfredo Berruti

ASST Spedali Civili Of Brescia
Brescia, IT 
Expertise in
18
conditions
ASST Spedali Civili Of Brescia
Brescia, IT 
OverviewLocationsClinical Research

Overview

Alfredo Berruti practices in Brescia, Italy. Mr. Berruti is highly rated in 18 conditions, according to our data. His top areas of expertise are Adrenocortical Carcinoma, Adrenal Cancer, Neuroendocrine Tumor, Orchiectomy, and Nephrectomy.

His clinical research consists of co-authoring 413 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

ASST Spedali Civili of Brescia
Brescia, 25123, Italy
Other Locations
ASST Spedali Civili di Brescia
Brescia, Italy
Policlinico Umberto I
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Enrollment Status: Completed
Publish Date: March 20, 2025
Intervention Type: Drug
Study Drug: Surufatinib
Study Phase: Phase 2
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Enrollment Status: Terminated
Publish Date: November 12, 2024
Intervention Type: Biological
Study Drugs: EO2041, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
Enrollment Status: Unknown
Publish Date: April 03, 2020
Intervention Type: Drug
Study Drugs: Netupitant+Palonosetron, Dexamethasone
Study Phase: Phase 3
View 3 Less Clinical Trials

413 Total Publications

Amoxicillin-Induced Atypical Exanthema in a Patient with EBV-Related Nasopharyngeal Carcinoma: A Case Report.
Amoxicillin-Induced Atypical Exanthema in a Patient with EBV-Related Nasopharyngeal Carcinoma: A Case Report.
Journal: Viruses
Published: February 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Berruti's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 59 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile